Janine Salter

11.7k total citations · 4 hit papers
86 papers, 8.8k citations indexed

About

Janine Salter is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, Janine Salter has authored 86 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 43 papers in Genetics and 43 papers in Cancer Research. Recurrent topics in Janine Salter's work include Estrogen and related hormone effects (38 papers), Breast Cancer Treatment Studies (37 papers) and HER2/EGFR in Cancer Research (36 papers). Janine Salter is often cited by papers focused on Estrogen and related hormone effects (38 papers), Breast Cancer Treatment Studies (37 papers) and HER2/EGFR in Cancer Research (36 papers). Janine Salter collaborates with scholars based in United Kingdom, United States and Australia. Janine Salter's co-authors include Mitch Dowsett, Roger A’Hern, Ian E. Smith, Margaret Hills, Simone Detre, Jack Cuzick, Geraldine Walsh, Emma M. Quinn, John Forbes and Anthony Howell and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Janine Salter

86 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

2011 1.5k citations Roger A’Hern, Janine Salter et al. profile →
Defects in regulation of apoptosis in caspase-2-deficient mice

1998 560 citations Janine Salter et al. profile →
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

2010 546 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

2011 540 citations Jack Cuzick, Mitch Dowsett et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Janine Salter

Since Specialization

Citations

This map shows the geographic impact of Janine Salter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janine Salter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janine Salter more than expected).

Fields of papers citing papers by Janine Salter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janine Salter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janine Salter. The network helps show where Janine Salter may publish in the future.

Co-authorship network of co-authors of Janine Salter

This figure shows the co-authorship network connecting the top 25 collaborators of Janine Salter. A scholar is included among the top collaborators of Janine Salter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janine Salter. Janine Salter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer 2014 ·Annals of Oncology ·Mónica Arnedos, (unknown), Maria Afentakis, Roger A’Hern, Margaret Hills, Janine Salter, I. E. Smith, Jorge S. Reis‐Filho, Mitch Dowsett	30
2	Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance 2013 ·Clinical Cancer Research ·Anita K. Dunbier, Zara Ghazoui, H Anderson, Janine Salter, Ashutosh Nerurkar, Peter Osin, Roger A’Hern, William R. Miller, Ian E. Smith, Mitch Dowsett	98
3	HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab 2013 ·Annals of Oncology ·Lila Zabaglo, (unknown), Josef Rüschoff, (unknown), Janine Salter, (unknown), (unknown), Urania Dafni, Martine Piccart, Marion Procter, Mitch Dowsett	22
4	Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study 2013 ·Breast Cancer Research and Treatment ·Maria Afentakis, Mitch Dowsett, Ivana Šestak, Janine Salter, Anthony Howell, Aman U. Buzdar, John Forbes, Jack Cuzick	12
5	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study 2012 ·Breast Cancer Research ·Katja Lundgren, Matthew Brown, Sílvia Pineda, Jack Cuzick, Janine Salter, Lila Zabaglo, Anthony Howell, Mitch Dowsett, Göran Landberg, (unknown)	73
6	Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer 2011 ·Clinical Cancer Research ·Zara Ghazoui, Francesca M. Buffa, Anita K. Dunbier, H Anderson, Tim Dexter, Simone Detre, Janine Salter, Ian E. Smith, Adrian L. Harris, Mitch Dowsett	26
7	Association between breast cancer subtypes and response to neoadjuvant anastrozole 2011 ·Steroids ·Anita K. Dunbier, H Anderson, Zara Ghazoui, Janine Salter, Joel S. Parker, Charles M. Perou, Ian E. Smith, Mitch Dowsett	37
8	Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer 2011 ·JNCI Monographs ·Mitch Dowsett, I. E. Smith, John Robertson, Lee Robison, (unknown), Liam Johnson, Janine Salter, Anita K. Dunbier, H Anderson, Zara Ghazoui, (unknown), Abigail Evans, (unknown), Abdulkadir İskender, Maggie Wilcox, Judith M. Bliss	53
9	A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer 2010 ·Clinical Cancer Research ·Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nick Orr, Marina Parton, Ian E. Smith, Jorge S. Reis‐Filho, Mitch Dowsett, Alan Ashworth, Nicholas C. Turner	222
10	Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study 2010 ·Journal of Clinical Pathology ·Suzanne Drury, Janine Salter, Frederick L. Baehner, Steven Shak, Mitch Dowsett	21
11	Who would have thought a single Ki67 measurement would predict long-term outcome? 2009 ·Breast Cancer Research ·Mitch Dowsett, Roger A’Hern, Janine Salter, Lila Zabaglo, Ian E. Smith	17
12	The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo 2007 ·Molecular Cancer Therapeutics ·Lesley‐Ann Martin, Julia E. Head, Sunil Pancholi, Janine Salter, Emma M. Quinn, Simone Detre, Stan B. Kaye, Angela Howes, Mitch Dowsett, Stephen Johnston	37
13	A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer 2007 ·Journal of Clinical Oncology ·Ian E. Smith, Geraldine Walsh, Anthony Skene, Antonio Llombart‐Cussac, José Mayordomo, Simone Detre, Janine Salter, Emma Clark, Patrick Magill, Mitch Dowsett	169
14	BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial 2006 ·Cancer Letters ·Zsofia Kote‐Jarai, Trevor J. Powles, Gillian Mitchell, Alwynne Tidy, S. Ashley, Douglas F. Easton, L. Assersohn, Nayanta Sodha, Janine Salter, Barry A. Gusterson, Mitch Dowsett, Rosalind A. Eeles	10
15	Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists 2005 ·Journal of Clinical Oncology ·Mitch Dowsett, (unknown), J. Michael Dixon, Anthony Skene, C.D.M. Griffith, Irene Boeddinghaus, Janine Salter, Simone Detre, Margaret Hills, S. Ashley, Stephen Francis, Geraldine Walsh, Ian E. Smith	229
16	Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. 2003 ·PubMed ·Giles Davies, Janine Salter, Margaret Hills, Lesley‐Ann Martin, Nigel Sacks, Mitch Dowsett	111
17	Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer 2003 ·British Journal of Cancer ·Caroline Archer, Marina Parton, Ian E. Smith, Peter Ellis, Janine Salter, S. Ashley, Gerald Gui, N Sacks, S. Ebbs, William Allum, N. Nasiri, Mitch Dowsett	71
18	Effects of the Aromatase Inhibitor Letrozole on Normal Breast Epithelial Cell Proliferation and Metabolic Indices in Postmenopausal Women 2002 ·Cancer Epidemiology and Prevention Biomarkers ·Catherine Harper‐Wynne, Gillian Ross, Nigel Sacks, Janine Salter, (unknown), (unknown), Roger A’Hern, Mitch Dowsett	5
19	HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. 2001 ·PubMed ·Mitch Dowsett, Catherine Harper‐Wynne, Irene Boeddinghaus, Janine Salter, Margaret Hills, Mike J. Dixon, (unknown), G P Gui, N Sacks, I. E. Smith	150
20	Oncogene Products and Other Diagnostic Markers in Human Breast Cancer Patients 1996 ·Annals of the New York Academy of Sciences ·Mitch Dowsett, Andreas Makris, Peter Ellis, Stephen Johnston, Janine Salter, Simone Detre, (unknown), Gloria Saccani‐Jotti, T.J. Powles, Ian E. Smith	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact